|
Multiple Myeloma (Kahler's Disease) – Pipeline Review, H1 2012
|
|||||||||||
| Preis** (Lieferformat): |
Versandkostenfrei ** WICHTIG: Alle Preise sind netto ausgewiesen. Abhängig von Versand- und Leistungsort ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Der korrekte Gesamtendpreis wird Ihnen mit der Angabe Ihrer Rechnungsadresse, USt-ID-Nr. etc. im Bestellverlauf ausgewiesen. Weitere Informationen zu den Bestandteilen des Kaufpreises finden Sie in unseren FAQs. |
Zahlen und Fakten zur Studie: | 274 seiten | |||||||||
| Inhalt der Studie: |
Introduction
Global Markets Direct’s, 'Multiple Myeloma (Kahler's Disease) - Pipeline Review, H1 2012', provides an overview of the Multiple Myeloma (Kahler's Disease) therapeutic pipeline. This repo.....
Introduction Global Markets Direct’s, 'Multiple Myeloma (Kahler's Disease) - Pipeline Review, H1 2012', provides an overview of the Multiple Myeloma (Kahler's Disease) therapeutic pipeline. This report provides information on the therapeutic development for Multiple Myeloma (Kahler's Disease), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Multiple Myeloma (Kahler's Disease). 'Multiple Myeloma (Kahler's Disease) - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Multiple Myeloma (Kahler's Disease). - A review of the Multiple Myeloma (Kahler's Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Multiple Myeloma (Kahler's Disease) pipeline on the basis of route of administration and molecule type. - Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Highlights Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Multiple Myeloma (Kahler's Disease). - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players with the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Multiple Myeloma (Kahler's Disease) pipeline depth and focus of Multiple Myeloma (Kahler's Disease) therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. [Studien Infos ausblenden] |
|||||||||||
|
Table of Contents Table of Contents 2 List of Tables 8 List of Figures 12 Introduction 13 Global Markets Direct Report Coverage 13 Multiple Myeloma (Kahler's Disease) Overview 14 Therapeutics Development 15 An Overview of Pipeline Products for Multiple Myeloma (Kahler's Disease) 15 Multiple Myeloma (Kahler's Disease) Therapeutics under Development by Companies 17 Multiple Myeloma (Kahler's Disease) Therapeutics under Investigation by Universities/Institutes 25 Late Stage Products 37 Comparative Analysis 37 Mid Clinical Stage Products 38 Comparative Analysis 38 Early Clinical Stage Products 39 Comparative Analysis 39 Discovery and Pre-Clinical Stage Products 40 Comparative Analysis 40 Multiple Myeloma (Kahler's Disease) Therapeutics – Products under Development by Companies 41 Multiple Myeloma (Kahler's Disease) Therapeutics – Products under Investigation by Universities/Institutes 53 Companies Involved in Multiple Myeloma (Kahler's Disease) Therapeutics Development 89 Bristol-Myers Squibb Company 89 Johnson & Johnson 90 Kyowa Hakko Kirin Co., Ltd. 91 Abbott Laboratories 92 Eli Lilly and Company 93 Viralytics Ltd. 94 GlaxoSmithKline plc 95 Seattle Genetics, Inc. 96 Genentech, Inc. 97 Gilead Sciences, Inc. 98 Biotest AG 99 Merck & Co., Inc. 100 Micromet, Inc. 101 Takeda Pharmaceutical Company Limited 102 BioSante Pharmaceuticals, Inc. 103 ZIOPHARM Oncology, Inc. 104 Millennium Pharmaceuticals, Inc. 105 Novartis AG 106 Cephalon, Inc. 107 Human Genome Sciences, Inc. 108 ImmunoGen, Inc. 109 Pfizer Inc. 110 Sunesis Pharmaceuticals, Inc. 111 SuperGen, Inc. 112 Genmab A/S 113 Cyclacel Pharmaceuticals Inc. 114 Celgene Corporation 115 Onyx Pharmaceuticals, Inc. 116 Incyte Corporation 117 Geron Corporation 118 MannKind Corporation 119 Merck KGaA 120 4SC AG 121 EntreMed, Inc. 122 Innate Pharma SA 148 Piramal Life Sciences Limited 149 SymBio Pharmaceuticals Limited 150 Chroma Therapeutics Ltd. 151 Avaris 152 Abiogen Pharma S.p.A. 153 Acceleron Pharma, Inc. 154 Aquinox Pharmaceuticals Inc. 155 Coronado Biosciences, Inc. 156 Arno Therapeutics, Inc. 157 Vaccinex, Inc. 158 CanBas Co., Ltd. 159 NovImmune SA 160 Axelar AB 161 Immune System Therapeutics Ltd. 162 Concert Pharmaceuticals, Inc. 163 NOXXON Pharma AG 164 Xencor, Inc. 165 Acetylon Pharmaceuticals, Inc. 166 Tragara Pharmaceuticals, Inc. 167 PharmaMar, S.A. 168 AB Science 169 Biokine Therapeutics Ltd. 170 Cylene Pharmaceuticals, Inc. 171 Nereus Pharmaceuticals, Inc. 172 AVEO Pharmaceuticals, Inc. 173 EUSA Pharma, Inc. 174 TAU Therapeutics, LLC 175 Immunovative Therapies, Ltd. 176 Multiple Myeloma (Kahler's Disease) – Therapeutics Assessment 177 Assessment by Monotherapy Products 177 Assessment by Combination Products 178 Assessment by Route of Administration 179 Assessment by Molecule Type 182 Drug Profiles 185 Perifosine - Drug Profile 185 LBH589 - Drug Profile 186 Carfilzomib - Drug Profile 188 Elotuzumab - Drug Profile 190 Aplidin - Drug Profile 192 Velcade + Cyclophosphamide + Dexamethasone - Drug Profile 193 Zolinza - Drug Profile 195 Velcade + Thalidomide + Dexamethasone - Drug Profile 197 Velcade + Dexamethasone - Drug Profile 199 Aplidin + Dexamethasone - Drug Profile 200 LBH589 + Bortezomib + Dexamethasone - Drug Profile 201 Revlimid + Dexamethasone - Drug Profile 203 Actimid + Dexamethasone - Drug Profile 205 Carfilzomib + Revlimid + Dexamethasone - Drug Profile 206 Actimid - Drug Profile 207 Tanespimycin + Velcade - Drug Profile 208 Melphalan + Prednisolone + Thalidomide - Drug Profile 210 Perifosine + Velcade + Dexamethasone - Drug Profile 211 Zolinza + Bortezomib - Drug Profile 212 LBH589 + Bortezomib - Drug Profile 213 Revlimid + Melphalan + Prednisone - Drug Profile 214 HuLuc63 + Lenalidomide + Dexamethasone - Drug Profile 215 Prednisolone - Drug Profile 218 Masitinib + Velcade + Dexamethasone - Drug Profile 219 Multiple Myeloma (Kahler's Disease) Therapeutics – Drug Profile Updates 220 Multiple Myeloma (Kahler's Disease) Therapeutics – Discontinued Products 233 Multiple Myeloma (Kahler's Disease) Therapeutics - Dormant Products 240 Multiple Myeloma (Kahler's Disease) – Product Development Milestones 262 Featured News & Press Releases 262 Jan 06, 2012: Immune System Therapeutics Announce Recruitment Of Patients With Kappa-Type Myeloma In Phase II Trial Of MDX-1097 262 Dec 26, 2011: SymBio Initiates Phase II Trial Of Bendamustine HCl In Multiple Myeloma In Japan 262 Dec 19, 2011: Patrys Provides Update On Upcoming Clinical Trial Program In Multiple Myeloma Patients 263 Dec 13, 2011: Presentations Highlight Results Of Studies With MLN9708, First Oral Proteasome Inhibitor In Early Stage Clinical Trials In Multiple Myeloma 264 Dec 13, 2011: Phase III Study Evaluating REVLIMID In Patients With High-Risk Smoldering Multiple Myeloma Presented At ASH 266 Dec 12, 2011: Celgene Announces Phase II Study Evaluates Clinical Benefit Of Pomalidomide In Heavily Pre-treated Patients With Multiple Myeloma 267 Dec 12, 2011: Acetylon Announces Publication Of Preclinical Pharmacokinetic, Pharmacodynamic And Bone Disease Results for ACY-1215 in Multiple Myeloma 268 Dec 12, 2011: BioInvent Presents New Preclinical Data Of BI-505 At American Society Of Hematology Annual Meeting 269 Dec 12, 2011: Biotest’s Clinical Development Of BT-062 In Multiple Myeloma Expands Into Combination Therapy 270 Dec 12, 2011: Phase III Study With REVLIMID Continuous Therapy Demonstrates Statistically Significant Improvement In Progression-Free Survival For Patients Newly Diagnosed With Multiple Myeloma 271 Appendix 273 Methodology 273 Coverage 273 Secondary Research 273 Primary Research 273 Expert Panel Validation 274 Contact Us 274 Disclaimer 274 [Inhaltsverzeichnis ausblenden] |
||||||||||||
|
List of Tables Number of Products Under Development for Multiple Myeloma (Kahler's Disease), H1 2012 15 Products under Development for Multiple Myeloma (Kahler's Disease) – Comparative Analysis, H1 2012 16 Number of Products under Development by Companies, H1 2012 18 Number of Products under Investigation by Universities/Institutes, H1 2012 26 Comparative Analysis by Late Stage Development, H1 2012 37 Comparative Analysis by Mid Clinical Stage Development, H1 2012 38 Comparative Analysis by Early Clinical Stage Development, H1 2012 39 Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012 40 Products under Development by Companies, H1 2012 41 Products under Investigation by Universities/Institutes, H1 2012 53 Bristol-Myers Squibb Company, H1 2012 89 Johnson & Johnson, H1 2012 90 Kyowa Hakko Kirin Co., Ltd., H1 2012 91 Abbott Laboratories, H1 2012 92 Eli Lilly and Company, H1 2012 93 Viralytics Ltd., H1 2012 94 GlaxoSmithKline plc, H1 2012 95 Seattle Genetics, Inc., H1 2012 96 Genentech, Inc., H1 2012 97 Gilead Sciences, Inc., H1 2012 98 Biotest AG, H1 2012 99 Merck & Co., Inc., H1 2012 100 Micromet, Inc., H1 2012 101 Takeda Pharmaceutical Company Limited, H1 2012 102 BioSante Pharmaceuticals, Inc., H1 2012 103 ZIOPHARM Oncology, Inc., H1 2012 104 Millennium Pharmaceuticals, Inc., H1 2012 105 Novartis AG, H1 2012 106 Cephalon, Inc., H1 2012 107 Human Genome Sciences, Inc., H1 2012 108 ImmunoGen, Inc., H1 2012 109 Pfizer Inc., H1 2012 110 Sunesis Pharmaceuticals, Inc., H1 2012 111 SuperGen, Inc., H1 2012 112 Genmab A/S, H1 2012 113 Cyclacel Pharmaceuticals Inc., H1 2012 114 Celgene Corporation, H1 2012 115 Onyx Pharmaceuticals, Inc., H1 2012 116 Incyte Corporation, H1 2012 117 Geron Corporation, H1 2012 118 MannKind Corporation, H1 2012 119 Merck KGaA, H1 2012 120 4SC AG, H1 2012 121 EntreMed, Inc., H1 2012 122 GENTIUM S.p.A., H1 2012 123 Celldex Therapeutics, Inc., H1 2012 124 AEterna Zentaris Inc., H1 2012 125 ImmunoCellular Therapeutics, Ltd., H1 2012 126 IMMUNOMEDICS, INC, H1 2012 127 Ligand Pharmaceuticals Incorporated, H1 2012 128 Avalon Pharmaceuticals, Inc., H1 2012 129 Cleveland BioLabs, Inc., H1 2012 130 Oncolytics Biotech Inc., H1 2012 131 Compugen Ltd., H1 2012 132 Patrys Limited, H1 2012 133 Curis, Inc., H1 2012 134 Keryx Biopharmaceuticals, Inc., H1 2012 135 Alexion Pharmaceuticals, Inc., H1 2012 136 Telik, Inc., H1 2012 137 CytRx Corporation, H1 2012 138 Pharmacyclics, Inc., H1 2012 139 Array BioPharma Inc., H1 2012 140 MorphoSys AG, H1 2012 141 BioInvent International AB, H1 2012 142 Senesco Technologies, Inc., H1 2012 143 Choongwae Pharma Corp, H1 2012 144 Quest PharmaTech Inc., H1 2012 145 Threshold Pharmaceuticals, Inc., H1 2012 146 CrystalGenomics, Inc., H1 2012 147 Innate Pharma SA, H1 2012 148 Piramal Life Sciences Limited, H1 2012 149 SymBio Pharmaceuticals Limited, H1 2012 150 Chroma Therapeutics Ltd., H1 2012 151 Avaris, H1 2012 152 Abiogen Pharma S.p.A., H1 2012 153 Acceleron Pharma, Inc., H1 2012 154 Aquinox Pharmaceuticals Inc., H1 2012 155 Coronado Biosciences, Inc., H1 2012 156 Arno Therapeutics, Inc., H1 2012 157 Vaccinex, Inc., H1 2012 158 CanBas Co., Ltd., H1 2012 159 NovImmune SA, H1 2012 160 Axelar AB, H1 2012 161 Immune System Therapeutics Ltd., H1 2012 162 Concert Pharmaceuticals, Inc., H1 2012 163 NOXXON Pharma AG, H1 2012 164 Xencor, Inc., H1 2012 165 Acetylon Pharmaceuticals, Inc., H1 2012 166 Tragara Pharmaceuticals, Inc., H1 2012 167 PharmaMar, S.A., H1 2012 168 AB Science, H1 2012 169 Biokine Therapeutics Ltd., H1 2012 170 Cylene Pharmaceuticals, Inc., H1 2012 171 Nereus Pharmaceuticals, Inc., H1 2012 172 AVEO Pharmaceuticals, Inc., H1 2012 173 EUSA Pharma, Inc., H1 2012 174 TAU Therapeutics, LLC, H1 2012 175 Immunovative Therapies, Ltd., H1 2012 176 Assessment by Monotherapy Products, H1 2012 177 Assessment by Combination Products, H1 2012 178 Assessment by Stage and Route of Administration, H1 2012 181 Assessment by Molecule Type, H1 2012 184 Multiple Myeloma (Kahler's Disease) Therapeutics – Drug Profile Updates 220 Multiple Myeloma (Kahler's Disease) Therapeutics – Discontinued Products 233 Multiple Myeloma (Kahler's Disease) Therapeutics – Dormant Products 240 List of Figures Number of Products under Development for Multiple Myeloma (Kahler's Disease), H1 2012 15 Products under Development for Multiple Myeloma (Kahler's Disease) – Comparative Analysis, H1 2012 16 Products under Development by Companies, H1 2012 17 Products under Investigation by Universities/Institutes, H1 2012 25 Late Stage Products, H1 2012 37 Mid Clinical Stage Products, H1 2012 38 Early Clinical Stage Products, H1 2012 39 Discovery and Pre-Clinical Stage Products, H1 2012 40 Assessment by Monotherapy Products, H1 2012 177 Assessment by Combination Products, H1 2012 178 Assessment by Route of Administration, H1 2012 179 Assessment by Stage and Route of Administration, H1 2012 180 Assessment by Molecule Type, H1 2012 182 Assessment by Stage and Molecule Type, H1 2012 183 [Tabellenverzeichnis ausblenden] |
||||||||||||
| Hinweis: | * Der Rechnungsbetrag für diese Studie wird in $ (Dollar) ausgewiesen. Kunden aus dem Inland bekommen von uns eine Rechnung in Euro, umgerechnet zum letztwöchigen Schlusskurs | |||||||||||
|
|
||||||||||||
